In partnership with
Monkey model of COVID-19 myocardial injury
Polypill plus aspirin for primary prevention of cardiovascular events
IV Iron slashes HF hospitalisations by 26%
Dapagliflozin reduces renal risk independent of CV disease status
Sotatercept improves right ventricular-pulmonary arterial coupling and right ventricular function
Mavacamten effective in obstructive hypertrophic cardiomyopathy
Clever trial design gets patients back on statins: the SAMSON trial
PIONEER III trial: Drug-eluting stents are comparable
AF screening benefit: the mHealth Screening to Prevent Strokes (mSTOPS) study
Sotagliflozin shows cardiorenal benefits in diabetes patients: 2 trials
Children exposed to tobacco smoke have worse heart function as adults
Extra imaging for women with heart attacks without blockage
Finerenone lowers CV events in diabetic CKD patients
Obese patients 50 years or younger have worse COVID-19 outcomes
No benefit from high-dose omega-3 for AF high-risk patients
Cardiovascular disease on outcomes among hospitalised COVID-19 patients
Lowering LDL cholesterol in older patients is beneficial
Transgender people have unaddressed heart disease risks
Top image: @ iStockPhoto: Noctiluxx
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP